The intent is to increases the country’s capacity to meet broader demand for testing in the coming months that is forecast to be millions of tests more per day than current capabilities.
Researchers based at the Beaumont Health System in Michigan, have developed a test using a method known as Reverse Transcription Loop-Mediated Isothermal Amplification or RT-LAMP, that does not require the repeated heating cycles of PCR.
A growing number of diagnostics developers have set out to address the challenge of meeting the nation’s need for more COVID-19 tests. Here we profile five companies that have answered that challenge by working to bring new assays, with new technologies, to patients.
10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
Personal Genome Diagnostics (PGDx) said it has applied the CE mark to its PGDx elio tissue complete assay, a distinction the company said will enable...
The research reveals that the LY6E protein impairs the coronavirus’ ability to initiate infection, which could lead to treatments for the illness.
Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto.
Company expects to deliver 50,000 tests per day of the rapid, instrument-based, isothermal system designed for qualitative detection of infectious diseases.
The researchers compared the lineage hierarchy of the developing human brain to the transcriptome of cancer cells. The team found that there are five main cancer cell types within each tumor, and these cancer cell types are similar to the cell types that are in the normal human brain.
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine